I am still not overly impressed by this drug, although I understand that it has been tested on heavily pre-treated patients with very aggressive/resistant cancers... but here it is!
BMS-986365, an investigational oral drug for metastatic castration-resistant prostate cancer (mCRPC), has shown promise in preclinical and early clinical trials and is now entering a global Phase 3 study, with recruitment at 230 sites starting in March 2025. The drug employs a dual mechanism, degrading the androgen receptor (AR) and antagonizing its activity, effectively targeting mutated AR forms that drive resistance. Early trials demonstrated significant benefits, including a PSA decline of 30% or more in 70% of patients at the highest dose, manageable side effects, and a median progression-free survival of 6.3 months.
If successful, BMS-986365 could address treatment resistance and offer new hope to patients with advanced, therapy-resistant prostate cancer.
Bayer announces positive topline results for NUBEQA® (darolutamide) from Phase III trial in men with mHSPC - July 17, 2024
Supraphysiological Androgens [SPA] Promote Tumor Suppressive Activity of the AR Through cMYC Repression and Recruitment of the DREAM Complex